Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends Sole Primary Endpoint

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's draft guidance for clinical trials of drugs for hospital-acquired or ventilator-associated bacterial pneumonia is strict, even compared with the draft guidance for community-acquired bacterial pneumonia.

You may also be interested in...

Sicker Patients In Ventilator-Associated Bacterial Pneumonia Could Make Trials Easier

Public/private working group’s “interim considerations” of how best to design clinical trials for VABP and hospital-acquired bacterial pneumonia would add symptom improvement to a mortality endpoint for the latter.

Antibiotic Resistance Gets Attention Of FDA, Congress

Both FDA and Congress are taking interest in combating antibiotic resistance, but FDA likely has more power to make headway in the near term, even as industry remains somewhat wary of that particular agenda item.

Telavancin Review Challenges Adequacy Of FDA’s Favored Mortality Endpoint

Clinical response data in Theravance’s nosocomial pneumonia studies are difficult to interpret because some patients died shortly after being deemed as cured, the agency says. However, FDA’s statistical reviewer concedes the problem may be a lack of specificity in the 28-day window for assessing mortality.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts